T 2099/15 of 20.11.2020
- European Case Law Identifier
- ECLI:EP:BA:2020:T209915.20201120
- Date of decision
- 20 November 2020
- Case number
- T 2099/15
- Petition for review of
- -
- Application number
- 06825074.5
- IPC class
- A61K 31/437C07D 487/04A61P 29/00
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS
- Applicant name
- Bristol-Myers Squibb Company
- Opponent name
- Bayer Pharma Aktiengesellschaft
- Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(c) (2007)European Patent Convention Art 56 (2007)European Patent Convention R 99(2) (2007)Rules of procedure of the Boards of Appeal Art 12(4) (2007)Rules of procedure of the Boards of Appeal Art 25(2) (2020)
- Keywords
- Grounds for opposition - amendments
Admissibility of appeal
Late-filed evidence - documents not admitted in first instance proceedings
Inventive step - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.